All In Biotech

Drug Trial Radar · NCT01600014

Ingenol Mebutate Gel, 0.015% Repeat Use for Multiple Actinic Keratoses on Face and Scalp

Last checked: Nov 20, 2026Latest source record: Mar 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 463 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

463

Actual

Start

May 2012

Primary completion

Feb 2014

Study completion Feb 2014

Sponsor

Lead sponsor
LEO PharmaIndustry
Sponsor type
Industry
First posted
May 16, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to demonstrate that ingenol mebutate gel is efficacious in treating Actinic Keratoses (AKs) present 8 weeks after initial field treatment or emerging in a previously cleared field.

Conditions

  • Actinic Keratosis

Interventions

  • Ingenol mebutate gel, 0.015%Drug

    Topical field treatment once daily for 3 consecutive days within a 25 cm2 treatment area on the face or scalp of AKs present or emerging after an initial treatment with ingenol mebutate gel, 0.015%

  • Vehicle gelDrug

    Topical field treatment once daily for 3 consecutive days within a 25 cm2 treatment area on the face or scalp of AKs present or emerging after an initial treatment with ingenol mebutate gel, 0.015%

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Complete Clearance of AKs 8 Weeks After RandomisationTime frame: 8 weeks after randomisation

Locations

13 sites in 5 countries. Site status is shown where the registry gives one.

  • St John of God Dermatology

    Subiaco, Australia

  • Stratica Medical

    Edmonton, Alberta, Canada

  • Skin Care Centre

    Vancouver, British Columbia, Canada

  • Dermadvances Research

    Winnipeg, Manitoba, Canada

  • Durondel C.P. Inc./Dermatology Clinic

    Moncton, New Brunswick, Canada

  • UltraNova Skincare

    Barrie, Ontario, Canada

  • SKiN Centre for Dermatology

    Peterborough, Ontario, Canada

  • Windsor Clinical Research Inc.

    Windsor, Ontario, Canada

  • Innovaderm Research Inc.

    Montreal, Quebec, Canada

  • Centre de Recherche Dermatologique

    Québec, Quebec, Canada

  • CHU de Nantes

    Nantes, Loire-Atlantique 6, France

  • Universitätsklinikum Tübingen

    Tübingen, Germany

  • Central Manchester University Hosptial

    Manchester, Greater Manchester, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.